## **CLAIMS**

## What is claimed is:

- 1. An isolated NET-4 modulator selected from the group consisting of an antisense oligonucleotide, a ribozyme, a protein, a polypeptide, and a small molecule.
- 5 2. The isolated NET-4 modulator of claim 1 wherein said NET-4 modulator is an antisense molecule.
  - 3. The isolated NET-4 modulator of claim 2 wherein said antisense molecule or the complement thereof comprises at least 15 consecutive nucleic acids of the sequence of SEQ ID NO:1.
  - 4. The isolated NET-4 modulator of claim 3 wherein said antisense molecule or the complement thereof hybridizes under high stringency conditions to the sequence of SEQ ID NO:1.
  - 5. The isolated NET-4 modulator of claim 2 wherein said antisense molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:2-6.
- 15 6. The isolated NET-4 modulator of claim 1 wherein said NET-4 modulator is selected from the group consisting of an antibody and an antibody fragment.
  - 7. The isolated NET-4 modulator of claim 6 wherein said antibody or antibody fragment is monoclonal.
- 8. The isolated NET-4 modulator of claim 7 wherein said antibody or antibody fragment is humanized.

15

- 9. A composition, comprising a therapeutically effective amount of a NET-4 modulator in a pharmaceutically acceptable carrier.
  - 10. The composition of claim 9, comprising two or more NET-4 modulators.
- The composition of claim 9 wherein said NET-4 modulator is an antisense molecule.
  - 12. A method of decreasing the expression of NET-4 in a mammalian cell, comprising administering to said cell a NET-4 inhibitor of claim 1.
  - 13. The method of claim 12 wherein said NET-4 modulator is an antisense molecule.
  - 14. The method of claim 13 wherein said antisense molecule or the complement thereof comprises at least 15 consecutive nucleic acids of the sequence of SEQ ID NO:1.
  - 15. The method of claim 13 wherein said antisense molecule or the complement thereof hybridizes under high stringency conditions to the sequence of SEQ ID NO:1.
  - 16. The method of claim 13 wherein said antisense molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:2-6.
  - 17. The method of claim 12 wherein said NET-4 modulator is selected from the group consisting of a protein and a polypeptide.

5

- 18. The method of claim 12 wherein said NET-4 modulator is a small molecule.
- 19. The method of claim 12 wherein said NET-4 modulator is administered *ex vivo* to said mammalian cell.
- 20. A method of treating neoplastic disease, comprising administering to a mammalian cell a NET-4 modulator of claim 1 such that said neoplastic disease is reduced in severity.
- 21. A diagnostic kit for detecting the presence of a colon tumor cell in a biological sample, said kit comprising at least one oligonucleotide selected from the group consisting of SEQ ID NOs:18, 19, 20, 21 and 22, and at least one control oligonucleotide that does not hybridize with a polynucleotide of SEQ ID NO:1 under stringent conditions.
  - 22. The kit of claim 21 comprising at least 3 of said oligonucleotides.
  - 23. The kit of claim 21 comprising said five oligonucleotides.